CorMedix Inc. (CRMD)

Market Cap	846.26M
Revenue (ttm)	82.55M
Net Income (ttm)	17.18M
Shares Out	74.43M
EPS (ttm)	0.28
PE Ratio	40.96
Forward PE	10.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,158,032
Open	11.36
Previous Close	11.36
Day's Range	11.14 - 11.41
52-Week Range	3.61 - 17.43
Beta	1.58
Analysts	Strong Buy
Price Target	17.33 (+52.42%)
Earnings Date	Aug 13, 2025

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Height...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2010
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: CRMD
• Website: https://www.cormedix.com

Analyst Summary

According to 7 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price target is $17.33, which is an increase of 52.42% from the latest price.

Price Target

$17.33

(52.42% upside)

Analyst Consensus: Strong Buy